Home › Onyx Snubbing Amgen Paves Way for 89% Premium: Real M&A
 

Keywords :   


Onyx Snubbing Amgen Paves Way for 89% Premium: Real M&A

2013-07-03 06:25:34| Biotech - Topix.net

Onyx Pharmaceuticals Inc. , which surged more than 50 percent after rejecting a bid from Amgen Inc., is betting that potential suitors from Bayer AG to Bristol-Myers Squibb Co.

Tags: real ma premium onyx

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
24.111000 15
24.11 nike soccer usa national team uniform
24.1160266
24.11 1
24.11
24.11GREATEST HITS ALTER EGO EGOIST
24.11(ALINCO)
24.11[]34
More »